パーソナライズド・フォール・プリヴェンション・イン・パーソナライズド・フォール・イン・パーソナライズド・フォール・イン・パーソナライズド・フォール・イン・パーソナライズド・フォール・イン・パーソナライズド・フォール
Per G Farup1,2, Knut Hestad1, Knut Engedal3,4
1Department of Research and Innovation, Innlandet Hospital Trust, P.O. Box 104, N-2381 Brumunddal, Norway.
Geriatrics (Basel, Switzerland)
|August 27, 2025
まとめ
パーソナライズされた転倒予防は 認知症の患者にとって極めて重要です 転倒のリスクとその予測要因は 歩行速度や日々の活動など 認知症の種類によって大きく異なっており 適切な介入が必要となります
科学分野:
- ゲロントロジー
- 神経学
- 公衆衛生
背景:
- 認知症における多因子転倒予防の効果は限られている.
- 認知障害のある個人に個別化された予防戦略が推奨されています.
- 以前の研究では 歩行速度,日常生活 (ADL) の活動,うつ病が 転倒を予測する 重要な要因だと分かりました
研究 の 目的:
- 身体的,精神的,認知的な機能に関連した個人特有の落下リスクを調査する.
- アルツハイマー病 (AD),血管性認知症 (VD),混合AD/VD (MixADVD),フロントテンポラル認知症 (FTD),およびレウィ体の認知症 (DLB) による転倒リスクの変動を調査する.
主な方法:
- ノルウェーの認知症状評価者登録簿 (NorCog) のデータを活用した.
- 認知症グループ間の違いを分析し,転倒,歩行速度,ADL,コーネルスコアを予測した.
主要な成果:
- 参加者の40. 7%が転倒を報告し,認知症の診断によって有意な変動がありました.
- 転倒の発生率は,年齢,併発症,多剤療法,うつ病,認知の変動,運動の低下,歩行速度,ADLと相関する.
- VDとMixADVDは高い転倒率を示し,DLBはうつ病と変動に関連した高い転倒リスクを示した.
結論:
- 転倒の発生率と予測要因は 認知症の種類によって大きく異なります
- 効果的な個別化介入には 個々の転倒リスク要因の理解が必要です
関連する概念動画
Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Coronary Artery Disease IV: Preventive Measures
32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
Peripheral Artery Disease IV: Nursing Management
43
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
43
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260


